The Pharma Data

JUNE 28, 2021

Vericiguat is being jointly developed with MSD (a tradename of Merck & Co., The vericiguat program is being co-developed by Bayer and MSD. The companies share equally the costs of the development of vericiguat. Kenilworth, NJ, USA). About Vericiguat Vericiguat 2.5 MSD has the commercial rights to vericiguat in the U.S.

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Additional Transaction Details. .:

Dermatology 52

Dermatology Cardiology Development Medicine 52

pharmaphorum

MAY 18, 2021

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

After each data review, the DSMC will advise the study Steering Committee with recommendations for protocol modifications, if concerns over safety have developed, or that the study should continue according to the protocol if no concerns are identified. About Cardiol Therapeutics. Cardiol Therapeutics Inc. ( alone exceeding $30 billion.

Trials 52

Trials Cardiology Containment Development 52

Delveinsight

JULY 22, 2021

Joachim Fruebis, chief development officer of BlueRock, said that receiving fast track designation from the FDA is a crucial step, which will help them further progress clinical development of their DA01 cell therapy approach for Parkinson’s disease.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

Drug Discovery World

OCTOBER 19, 2022

The drop in recruiting sites in Ukraine and in Russia sadly confirms our earlier prediction that the impact of war in the region on clinical development, and most importantly on patients, is considerable. Clinic+, based in the capital Kyiv, where fighting has been particularly severe since the start of the war. .

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

MAY 31, 2022

Senior Vice President, Clinical Development, BlueRock Therapeutics. “We We are excited that our Phase 1 clinical trial has completed enrollment and believe it is a critical next step toward the development of a novel cell therapy that has the potential to transform the treatment landscape for this devastating disease.”.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

The Pharma Data

JULY 12, 2021

Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. The clinical data from FIGARO-DKD are scheduled for presentation at the European Society of Cardiology (ESC) Congress 2021 on August 28th. Up to 40% of all patients with type 2 diabetes develop CKD. The study met its primary endpoint.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

NOVEMBER 5, 2021

EMPEROR Program clinical investigator and Emeritus Professor of Rectifiers and Cardiology at the University of Lorraine, France.”The vice chairman, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals,Inc.”The ” TheU.S. .”We

Trials 52

Trials Cardiology Drugs Development 52

The Pharma Data

NOVEMBER 8, 2021

The cardiology ballot at Bayer formerly includes a number of products and several other composites in colorful stages of preclinical and clinical development. Bayer is committed to drive sustainable development and induce a positive impact with its businesses.

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

The Pharma Data

OCTOBER 28, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Bayer is committed to drive sustainable development and generate a positive impact with its businesses.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

The Pharma Data

AUGUST 30, 2021

Professor of Cardiology at the National and Kapodistrian University of Athens, Greece, and co-principal investigator of the FIDELIO-DKD and FIGARO-DKD Phase III clinical trials. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease.

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 11, 2021

Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.

Medicine 52

Medicine Insulin FDA Approval Trials 52

XTalks

NOVEMBER 19, 2021

While cardiac biomarkers hold much promise, there are a number of challenges in developing robust markers that can accurately reflect changes in disease biology linked to the mechanism of action of a therapeutic intervention. This is a part of the precision cardiology approach and could lead to their use as prognostic indicators.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

NOVEMBER 11, 2021

Bayer and its development mate MSD moment blazoned the launch of VICTOR (VerICiguaT in grown-ups with Habitual heart failure and Reduced ejection bit), a new Phase III cardiovascular study probing the expanded use of heart failure (HF) treatment vericiguat. The vericiguat program is beingco-developed by Bayer and MSD.

Cardiology 40

Cardiology Branding Development Production 40

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

OCTOBER 8, 2020

Clinical development of the system got off the ground last year when the company announced the closure of a £2.15m financing round. Developed at the city’s St Bartholomew’s Hospital, the system was developed by a team including London-based cardiologist Richard Schilling.

Trials 52

Trials Clinical Trials Clinical Trials Clinical Development 52

The Pharma Data

JULY 8, 2021

. “No approved therapies have been clinically proven to improve outcomes specifically for people with HFpEF, leaving a significant unmet medical need in this already prevalent and increasingly common form of heart failure,” said Mohamed Eid, M.D., vice president, Product Development, Lilly. Va ginal yeast infection.

Trials 52

Trials Doctors Doctor Medicine 52

The Pharma Data

SEPTEMBER 15, 2020

(NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52